Recursion Pharmaceuticals Inc (RXRX) - Net Assets
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has net assets worth $1.02 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.34 Billion) and total liabilities ($314.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Recursion Pharmaceuticals Inc operating cash flow efficiency to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.02 Billion |
| % of Total Assets | 76.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | 108.29% |
| 10-Year Change | N/A |
| Growth Volatility | 54.7 |
Recursion Pharmaceuticals Inc - Net Assets Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Recursion Pharmaceuticals Inc (RXRX) total assets for the complete picture of this company's asset base.
Annual Net Assets for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual net assets of Recursion Pharmaceuticals Inc from 2019 to 2025. For live valuation and market cap data, see market value of Recursion Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.13 Billion | +9.29% |
| 2024-12-31 | $1.03 Billion | +123.28% |
| 2023-12-31 | $463.44 Million | -4.60% |
| 2022-12-31 | $485.81 Million | -10.52% |
| 2021-12-31 | $542.94 Million | +363.19% |
| 2020-12-31 | $-206.29 Million | -66.01% |
| 2019-12-31 | $-124.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Recursion Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 194940700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $36.72 Million | 3.25% |
| Other Components | $3.17 Billion | 280.33% |
| Total Equity | $1.13 Billion | 100.00% |
Recursion Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Corporate Travel Management Ltd
AU:CTD
|
$1.66 Billion |
|
Robertet SA
PA:RBT
|
$1.66 Billion |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
$1.66 Billion |
|
Personal Assets Trust plc
LSE:PNL
|
$1.66 Billion |
|
Sionna Therapeutics, Inc. Common Stock
NASDAQ:SION
|
$1.66 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
$1.66 Billion |
|
Zhuzhou Times New Material Technology Co Ltd
SHG:600458
|
$1.66 Billion |
|
Faraday Technology Corp
TW:3035
|
$1.66 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Recursion Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,034,782,000 to 1,130,865,000, a change of 96,083,000 (9.3%).
- Net loss of 644,759,000 reduced equity.
- New share issuances of 528,864,000 increased equity.
- Other comprehensive income increased equity by 44,354,000.
- Other factors increased equity by 167,624,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-644.76 Million | -57.01% |
| Share Issuances | $528.86 Million | +46.77% |
| Other Comprehensive Income | $44.35 Million | +3.92% |
| Other Changes | $167.62 Million | +14.82% |
| Total Change | $- | 9.29% |
Book Value vs Market Value Analysis
This analysis compares Recursion Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.75 | $3.17 | x |
| 2020-12-31 | $-1.24 | $3.17 | x |
| 2021-12-31 | $3.19 | $3.17 | x |
| 2022-12-31 | $2.77 | $3.17 | x |
| 2023-12-31 | $2.23 | $3.17 | x |
| 2024-12-31 | $3.77 | $3.17 | x |
| 2025-12-31 | $2.53 | $3.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Recursion Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -863.35%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.30x
- Recent ROE (-57.01%) is below the historical average (-36.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -3654.30% | 0.02x | 0.00x | $-50.10 Million |
| 2020 | 0.00% | -2549.25% | 0.01x | 0.00x | $-66.38 Million |
| 2021 | -32.80% | -1780.74% | 0.02x | 1.12x | $-232.37 Million |
| 2022 | -49.28% | -603.36% | 0.06x | 1.44x | $-288.00 Million |
| 2023 | -70.79% | -747.71% | 0.07x | 1.41x | $-374.41 Million |
| 2024 | -44.81% | -788.02% | 0.04x | 1.40x | $-567.14 Million |
| 2025 | -57.01% | -863.35% | 0.05x | 1.30x | $-757.85 Million |
Industry Comparison
This section compares Recursion Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Recursion Pharmaceuticals Inc (RXRX) | $1.02 Billion | 0.00% | 0.31x | $1.66 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more